Our investors have a successful track record in protein therapeutics. Their backing and support emboldens our mission to fulfill the therapeutic promise of Physiocrines. As the exclusive developer of therapeutics directed to Physiocrine biology, aTyr is focused on building a strong, sustainable business of discovering and developing vital, new medicines for patients.
Alta Partners is a San Francisco-based venture capital firm focused on life sciences investing. Founded in 1996, the firm currently manages $2 billion in committed capital through eight venture fund programs. Alta invests in life sciences companies across the development continuum, from company formation to later-stage opportunities, and has funded more than 110 companies in the sector to date.
With more than $300 million under management, Cardinal Partners is a leading early-stage venture capital firm that seeks investment opportunities across the healthcare sector including life sciences, medical devices, and healthcare information technology.
Cardinal’s management team leverages their decades of experience to nurture today’s enterprises into tomorrow’s industry leaders. Together, the Cardinal Partners team has invested in over a hundred growth companies. Cardinal Partners is based in Princeton, New Jersey and also has offices in Laguna Beach, California and Wayne, Pennsylvania.
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2.4 billion of capital under management, Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The partners of Domain have a total of more than 200 years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 230 life-sciences companies. Domain is headquartered in Princeton, NJ with a second office in San Diego, CA.
Dr. Schimmel is an Ernst and Jean Hahn Professor at The Skaggs Institute for Chemical Biology at The Scripps Research Institute. In addition to founding aTyr, Dr. Schimmel has founded or co-founded a number of groundbreaking biotechs including Alkermes, Alnylam Pharmaceuticals, Cubist Pharmaceuticals, Metabolon, Repligen Corp., Sirtris Pharmaceuticals. He currently serves on the board of directors for Alnylam, Sirtris and Momenta Pharmaceuticals and serves on the scientific advisory board for Alnylam, Illumina, Sirtris, and Metabolon. He has previously served on the board of directors of Alkermes, ActivX, Avicena and Repligen.
Established in 1996, with offices in Waltham and Seattle, Polaris has more than $3 billion under management. Polaris Partners have helped build numerous market leading companies, including Accordant Health Services, Advanced Inhalation Research, Akamai Technologies, Allaire, Alnylam Pharmaceuticals, American Superconductor, Aspect Medical Systems, Avici Systems, Centra Software, Classifieds2000, deCODE genetics, Exchange.com, Matrics, Microbia, Momenta Pharmaceuticals, Paradigm Genetics, Powersoft, PSCI, SolidWorks and TransForm Pharmaceuticals.